SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A 52-week, randomized, double-blind phase 2 trial compared five once-daily semaglutide doses with liraglutide and matched placebo, alongside diet and physical-activity counseling. Percentage weight loss at week 52 was the primary outcome.
- Who / model studied
- The trial randomized 957 adults without diabetes who had BMI of at least 30 across 71 sites in eight countries.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Estimated weight loss was 2.3% with placebo, 6.0% to 13.8% across semaglutide groups and 7.8% with liraglutide. Every semaglutide dose outperformed placebo; doses of 0.2 mg or more outperformed liraglutide. Dose-related gastrointestinal symptoms, mainly nausea, were most common.
- Limitations & context
- No author-stated limitation was included in the abstract. Week-52 weight data were available for 93% of participants, and participants and investigators knew the target dose despite being masked to treatment assignment.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(18)31773-2